Avoid This Biotech Stock

Editor's note: This article is a stock pitch made by a member on CAPS, The Motley Fool's free investing community. The pitch is published UNEDITED and is the opinion of the CAPS member whose pitch it is, in this case:TSIF.

Each week, Motley Fool editors cull a top stock idea from the pitches made on CAPS, The Motley Fool's 180,000-member free investing community. Want your idea considered for this series? Make a compelling pitch on CAPS with a minimum length of 400 words. Want to follow our weekly picks? Subscribe to our RSS feed or follow us on Twitter.


Peregrine Pharmaceuticals (NAS: PPHM)

Submitted by


Member Rating


Submitted on

Dec. 6, 2011

Stock Price at Underperform Recommendation


Peregrine Pharmaceuticals profile

Star Rating



Tustin, Calif.



Market Cap

$96.2 million

Industry Peers

YM BioSciences (ASE: YMI)

Dendreon (NAS: DNDN)

OXiGENE (Nasdaq : OXGN)

Source: S&P Capital IQ, Yahoo! Finance, and Motley Fool CAPS.

This Week's Pitch:

Peregrine Pharmaceuticals has been lingering on my watch list for a few years. I had a piece of them back in 2009 before the 1:5 reverse split and the share price drops left me with little and I realized that the endgame was much further out than I had been playing it.

I only downthumb the 50% spike today that was caused by positive study results on Bavituximab, for reduction of lung cancer tumors, because it is "still early" and investors are far from patient at this stage. The drug is a combo drug used with other chemo drugs and appears to have similar results as Roche's Avastin. The market is sufficiently sized for them to be a nice play if they complete trials, prove safety, prove efficiency and get approval from the FDA but when a drug is already on the market the tendency of the FDA is to be stricter on the followers. Since it is being use with other drugs then results can be harder to measure. A 37% improvement with baxituximab vs 26% with only stand-alone drugs is significant, but will be difficult to correlate to survival benefit and against Roche's Avastin. 2012 is dedicated to longer term studies. Eventually the drug may be useable for other tumors.

In the short run we have a $30 Million per year cash burn rate and only $16 Million in cash. All funding so far has been from dilutive stock issue. Overall the company's stock can suppot more shares issued if it's successful in the end, BUT intermediate investors, those who pop in and pop out, usually with inconsistent expectations as I did two years ago, are not going to ride through the gyrations.

Short term thumb back down, will keep watching as data develops and a date with the FDA can be considered.

Follow this!
Want to follow our weekly picks? Subscribe to our RSS feed or follow us on Twitter.

At the time thisarticle was published The Motley Fool is investors writing for investors.Dan Dzombakdid not have a position in any of the companies mentioned in this article. Pitches must be compelling, made in the past 30 days, and be at least 400 words.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.